HC Wainwright Estimates Sight Sciences Q3 Earnings

Sight Sciences, Inc. (NASDAQ:SGHT) – Analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of Sight Sciences in a note issued to investors on Thursday, October 15th. HC Wainwright analyst Y. Chen anticipates that the company will post earnings per share of ($0.08) for the quarter. HC Wainwright currently has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Sight Sciences’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Sight Sciences’ Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.40) EPS and FY2027 earnings at ($0.24) EPS.

Several other research firms have also recently issued reports on SGHT. Wall Street Zen upgraded shares of Sight Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Sight Sciences in a research report on Friday, August 7th. UBS Group lifted their price objective on shares of Sight Sciences from $7.00 to $8.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Citigroup upped their price objective on shares of Sight Sciences from $8.00 to $10.00 and gave the stock a “neutral” rating in a research report on Monday, October 5th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.25.

Sight Sciences Price Performance

Shares of NASDAQ SGHT opened at $8.62 on Monday. The stock has a market capitalization of $474.88 million, a price-to-earnings ratio of -15.39 and a beta of 2.45. Sight Sciences has a 12 month low of $3.38 and a 12 month high of $9.71. The firm’s 50 day simple moving average is $8.45 and its 200-day simple moving average is $6.17. The company has a debt-to-equity ratio of 0.58, a current ratio of 4.95 and a quick ratio of 4.67.

Sight Sciences (NASDAQ:SGHT) last issued its earnings results on Wednesday, August 5th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.10. The firm had revenue of $23.39 million for the quarter, compared to the consensus estimate of $21.72 million. Sight Sciences had a negative return on equity of 43.39% and a negative net margin of 35.69%.

Insider Activity at Sight Sciences

In other Sight Sciences news, CTO David Badawi sold 7,797 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $9.05, for a total transaction of $70,562.85. Following the completion of the transaction, the chief technology officer directly owned 1,975,075 shares in the company, valued at approximately $17,874,428.75. This represents a 0.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Paul Badawi sold 29,653 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $9.05, for a total transaction of $268,359.65. Following the transaction, the chief executive officer directly owned 6,092,819 shares in the company, valued at approximately $55,140,011.95. The trade was a 0.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 47,646 shares of company stock worth $429,157 over the last 90 days. 30.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of Sight Sciences in the second quarter worth approximately $16,710,000. Dimensional Fund Advisors LP increased its position in shares of Sight Sciences by 13.4% during the first quarter. Dimensional Fund Advisors LP now owns 341,681 shares of the company’s stock worth $1,288,000 after purchasing an additional 40,346 shares in the last quarter. Renaissance Technologies LLC raised its stake in Sight Sciences by 6.3% in the 1st quarter. Renaissance Technologies LLC now owns 293,358 shares of the company’s stock valued at $1,106,000 after purchasing an additional 17,458 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Sight Sciences in the 2nd quarter valued at $908,000. Finally, Bank of America Corp DE purchased a new position in Sight Sciences in the 2nd quarter valued at $520,000. Institutional investors and hedge funds own 55.51% of the company’s stock.

About Sight Sciences

Sight Sciences, Inc is a medical technology company focused on developing and commercializing treatments for ophthalmic diseases. The company designs devices intended to address underlying causes of conditions such as glaucoma and dry eye disease, with an emphasis on less invasive procedures that can be performed in clinical settings.

Its product portfolio includes the OMNI Surgical System, a device used in minimally invasive glaucoma surgery to perform canaloplasty and trabeculotomy procedures.